Study suggests soy intake can promote heart, bone health
NORTHRIDGE, Calif. New findings published in the April issue of the Journal of Nutrition suggest soy foods can play an important role in promoting heart and bone health.
“Each year, the amount of research conducted on the health effects of soy and soybean components continues to impress,” stated Mark Messina, author of the report and professor of nutrition at Loma Linda University. “The research presented on soy and heart and bone health showed strong rationale for people to include soy in their diets.”
According to a meta-analysis that was part of the review, soy in the diet netted a reduction in LDL cholesterol of approximately 5%, which is in line with other data. Over time, a 5% reduction in LDL cholesterol can reduce heart disease risk from 10 to 15%.
“Although modest compared to cholesterol-lowering drugs like statins, the cholesterol-lowering effects of soy protein are similar to those of soluble fiber and certainly relevant from a public health perspective,” stated Messina. “Integrating a variety of heart-healthy foods – like soy, beans, nuts and certain vegetables – together into a healthy lifestyle are really the best approach to heart health.”
Study: Mortality increases in ICU patients with controlled glucose levels
WALTHAM, Mass. Intensive glucose control increased mortality among adults in the intensive care unit, according to a study published Tuesday on the New England Journal of Medicine’s Web site.
A blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter.
The findings call into question the optimal target range for blood glucose in critically ill patients, authors suggested. Medicating patients to bring down their blood sugar levels may raise the overall death rate by 10%, according to published reports on the research. Researchers estimated that one in every 38 patients aggressively treated for high blood sugar would die.
The study encompassed 6,104 people in Australia, New Zealand, Canada and the United States — only 20% of the patients included in the study had a history of diabetes.
Bausch & Lomb appoint new CFO, corporate VP
ROCHESTER, N.Y. Bausch & Lomb on Wednesday named Brian Harris its CFO and corporate VP, effective immediately.
“[Harris] brings not only his considerable financial acumen to Bausch & Lomb, but also the perspectives of a seasoned executive with on-the-ground operating experience in the U.S., Asia and Europe,” stated Gerald Ostrov, B&L chairman and CEO. “We expect him to immediately contribute to the company as we focus on driving profitable long-term growth.”
Beginning in 1989, Harris held positions of increasing responsibility with Tomkins, the industrial, automotive, building products and engineering manufacturing conglomerate. These included roles as president of the $2 billion worldwide power transmission business for Gates Corporation, as well as SVP for strategic business development, and CFO and company secretary. He also served as president of Gates Unitta Asia, the company’s Japanese joint venture.
Harris earned his Bachelor of Accountancy from Glasgow University, and qualified as a Scottish Chartered Accountant.
Jurij Kushner, B&L corporate VP, who has served as interim CFO since January 2009, will retire as planned from the company after a brief transition.